Noncommunicable diseases, access to essential medicines and universal health coverage

References

• World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. Geneva: World Health Organization; 2013.
   Google Scholar
• Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017 Sep 16;390:1151–5.
   PubMed Web of Science ®Google Scholar
• Nugent R, Bertram MY, Jan S, et al. Investing in non-communicable disease prevention and management to advance the sustainable development goals. Lancet. 2018 May 19;391:2029–2035.
   PubMed Web of Science ®Google Scholar
• Magnusson RS, Patterson D. The role of law and governance reform in the global response to non-communicable diseases. Global Health. 2014 Jun;5:44.
   Web of Science ®Google Scholar
• Collaborators GBDRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017 Sep 16;390:1345–1422.
   PubMed Web of Science ®Google Scholar
• Rasanathan K, Krech R. Action on social determinants of health is essential to tackle noncommunicable diseases. Bull World Health Organ. 2011 Oct 1;89:775–776.
   Web of Science ®Google Scholar
• Kluge H, Galea G, Figueras J, et al. Improving NCD outcomes: do health systems matter? In: Jakab M, Farrington J, Borgermans L, editors. Health systems respond to NCDs: time for ambition. Copenhagen: WHO Regional Office for Europe; 2018. p. 2–16.
   Google Scholar
• World Health Organization. Time to deliver: report of the WHO independent high-level commission on noncommunicable diseases. Geneva: World Health Organization; 2018.
   Google Scholar
• World Health Organization. NCD mortality and morbidity. Geneva: World Health Organization; 2018. cited 2019 Jun 26. Available from https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
   Google Scholar
• Lee JT, Hamid F, Pati S, et al. Impact of noncommunicable disease multimorbidity on healthcare utilisation and out-of-pocket expenditures in middle-income countries: cross sectional analysis. PLoS One. 2015;10:e0127199.
   PubMed Web of Science ®Google Scholar
• Beran D, Atlan-Corea C, Tapia B, et al. Report on the Rapid Assessment Protocol for Insulin Access in Nicaragua. Managua: International Insulin Foundation and Handicap International; 2007.
   Google Scholar
• Damasceno A, Azevedo A, Silva-Matos C, et al. Hypertension prevalence, awareness, treatment, and control in Mozambique: urban/rural gap during epidemiological transition. Hypertension. 2009 Jul;54:77–83.
   PubMed Web of Science ®Google Scholar
• Schneider P, Volger S. Pharmaceutical pricing and reimbursement reform in Kyrgyztsan. Copenhagen: WHO Regional Office for Europe; 2016.
   Google Scholar
• World Health Organization. Out-of-pocket expenditure as a percentage of total expenditure on health: 2014. Geneva: World Health Oragnization; 2017. cited 2018 Jun 25. Available from http://gamapserver.who.int/gho/interactive_charts/health_financing/atlasi5.html?indicator=i5
   Google Scholar
• OECD. Pharmaceutical spending (indicator): OECD; 2018 [cited 2018 Jun 28]. Available from: https://data.oecd.org/healthres/pharmaceutical-spending.htm
   Google Scholar
• World Health Organization Regional Office for the Western Pacific. How pharmaceutical systems are organized in Asia and the Pacific. Manila: World Health Organization Regional Office for the Western Pacific; 2018.
   Google Scholar
• World Health Organization. The world medicines situation 2011 - Medicine expenditures. Geneva: World Health Organization; 2011.
   Google Scholar
• Kelly BB, Koehlmoos TP, Nugent R. Exploring country-level decision making for the control of chronic diseases: reflections from an institute of medicine workshop. Glob Heart. 2012 Mar;7:7–12.
   Google Scholar
• Hoen T, Meyer E, Durisch S, et al. Improving affordability of new essential cancer medicines. Lancet Oncol. 2019;20:1052–1054.
   Web of Science ®Google Scholar
• World Health Organization and the International Bank for Reconstruction and Development/The World Bank. Tracking universal health coverage: 2017 global monitoring report. 2017.
   Google Scholar
• World Health Organization. The world health report 2010: health system financing: the path to universal coverage. Geneva: World Health Organization; 2010.
   Google Scholar
• Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017 Jan 28;389:403–476.
   PubMed Web of Science ®Google Scholar
• Schneider P, Vogler S. Pharmaceutical pricing and reimbursement reform in Kyrgyzstan. Copenhagen: WHO Regional Office for Europe; 2016.
   Google Scholar
• Ukraine Crisis Media Center. Ministry of Healthcare: 20 foreign and 15 Ukrainian manufacturers and 1,400 pharmacies join the program “Affordable medicine” 2017 [cited 2018 Jul 9]. Available from: http://uacrisis.org/54695-dostupni-liki-moz
   Google Scholar
• de-Graft Aikins A, Kushitor M, Koram K, et al. Chronic non-communicable diseases and the challenge of universal health coverage: insights from community-based cardiovascular disease research in urban poor communities in Accra, Ghana. BMC Public Health. 2014;14:S3.
   PubMed Web of Science ®Google Scholar
• World Health Organization Regional Office for Europe. Medicines reimbursement policies in Europe Copenhagen: WHO regional office for Europe; 2018 [cited 2018 Oct 20]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/376625/pharmaceutical-reimbursement-eng.pdf?ua=1
   Google Scholar
• Tang S, Brixi H, Bekedam H. Advancing universal coverage of healthcare in China: translating political will into policy and practice. Int J Health Plann Manage. 2014 Apr-Jun;29:160–174.
   PubMed Web of Science ®Google Scholar
• Tangcharoensathien V, Witthayapipopsakul W, Panichkriangkrai W, et al. Health systems development in Thailand: a solid platform for successful implementation of universal health coverage. Lancet. 2018 Mar 24;391:1205–1223.
   PubMed Web of Science ®Google Scholar
• Cockburn R, Newton PN, Agyarko EK, et al. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005 Apr;2:e100.
   PubMed Web of Science ®Google Scholar
• Newton PN, Green MD, Fernandez FM, et al. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006 Sep;6:602–613.
   PubMed Web of Science ®Google Scholar
• Newton P. N., Green MD, Fernandez F. M. Impact of poor-quality medicines in the ‘developing’ world. Trends Pharmacol Sci. 2010 Mar;31:99–101.
   PubMed Web of Science ®Google Scholar
• Caudron JM, Ford N, Henkens M., et al. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health. 2008 Aug;13:1062–1072.
   PubMed Web of Science ®Google Scholar
• Twagirumukiza M, Cosijns A, Pringels E, et al. Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg. 2009 Nov;81:776–781.
   Web of Science ®Google Scholar
• Antignac M, Diop BI, Macquart de Terline D, et al. Fighting fake medicines: first quality evaluation of cardiac drugs in Africa. Int J Cardiol. 2017;15:523–528.
   Web of Science ®Google Scholar
• Chow CK, Ramasundarahettige C, Hu W, et al. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes Endocrinol. 2018 Oct;6(10):798–808.
   Web of Science ®Google Scholar
• Niens LM, Cameron A, Van de Poel E, et al. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med. 2010;7.
   Web of Science ®Google Scholar
• World Health Organization, Health Action International. Measuring medicine prices, availability, affordability and price components (WHO/PSM/PAR/2008.3). 2nd ed. Geneva: World Health Organization; 2008.
   Google Scholar
• United Nations. Indicator 3.b.3: proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis. New York, NY: United Nations Statistics Division, Development Data and Outreach Branch; 2019. cited 2019 Apr 9. Available from https://unstats.un.org/sdgs/metadata/files/Metadata-03-0B-03.pdf
   Google Scholar
• Robertson J, Mace C, Forte G, et al. Medicines availability for non-communicable diseases: the case for standardized monitoring. Global Health. 2015 May;7:18.
   Web of Science ®Google Scholar
• Bigdeli M, Peters D, Wagner A. Medicines in health systems: advancing access, affordability and appropriate use. Geneva: World Health Organization; 2014.
   Google Scholar
• Hogerzeil HV, Liberman J, Wirtz VJ, et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet. 2013 Feb 23;381:680–689.
   PubMed Web of Science ®Google Scholar
• Simao M, Wirtz VJ, Al-Ansary LA, et al. A global accountability mechanism for access to essential medicines. Lancet. 2018 Dec 8;392:2418–2420.
   Web of Science ®Google Scholar
• Rockers PC, Wirtz VJ, Umeh CA, et al. Industry-led access-to-medicines initiatives in low- and middle-income countries: strategies and evidence. Health Aff (Millwood). 2017 Apr 1;36:706–713.
   PubMed Web of Science ®Google Scholar
• Silverman R, Keller J, Glassman A, et al. Tackling the triple transition in global health procurement. Washington DC: Center for Global Development; 2019.
   Google Scholar
• Beran D, Ewen M, Lipska K, et al. Availability and affordability of essential medicines: implications for global diabetes treatment. Curr Diab Rep. 2018 Jun 16;18:48.
   PubMed Web of Science ®Google Scholar